Duloxetine hydrochloride sustained-release medicine is composed of duloxetine hydrochloride and acceptable excipients in oral medicine, wherein duloxetine hydrochloride is 15% to 65% of the total weight of the drug, and the excipients are At least include polymer matrix slow-release materials, release rate regulating components and enteric coating materials, and polymer matrix slow-release materials are 1% to 80%, release rate regulating components are 0.1% to 50%, enteric coating materials The coating material is 1.5% to 10%. The drug has a skeleton-type slow-release function of intestinal erosion, quick onset, strong drug effect, and prolonged action time, which can significantly reduce the adverse reactions of instantaneous drug release after taking the drug, make the blood drug concentration and drug effect more stable and durable, and enhance Patient compliance and clinical treatment outcomes.